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Potential of mitochondrial membrane
A B S T R A C T
Two cellular proteins encoded by the breast and ovarian cancer type 1 susceptibility (BRCA1 and BRCA2)
tumor suppressor genes are essential for DNA integrity and the maintenance of genomic stability.
Approximately 5–10% of breast and ovarian cancers result from inherited alterations or mutations in
these genes.
Remarkably, BRCA1/BRCA2-deﬁcient cells are hypersensitive to selective inhibition of poly(ADP-
ribose)polymerase 1 (PARP-1), whose primary functions are related to DNA base excision repair; PARP-1
inhibition signiﬁcantly potentiates the cytotoxicity of various anti-cancer drugs, including inhibitors of
topoisomerase I and II.
In the present study, we examined the anti-proliferative and pro-apoptotic effects of C-1305, a
selective inhibitor of topoisomerase II, on human breast cancer cell lines with different BRCA1 and p53
statuses. BRCA1-competent breast cancer cell lines exhibited different responses to topoisomerase II
inhibition. BT-20 cells that express high levels of BRCA1 levels were most resistant to C-1305 than other
tested cells. Surprisingly, pharmacological interference with PARP-1 activity strongly inhibited their
proliferation and potentiated the efﬁcacy of C-1305 treatment. In contrast, PARP-1 inhibition only
weakly affected the proliferation of BRCA1-deﬁcient SKBr-3 cells and was not synergistic with the effects
of C-1305. Further experiments revealed that the inhibition of PARP-1 in BT-20 cells caused the
accumulation of DNA strand breaks and induced caspase-3 dependent apoptosis. These results seem to
indicate that PARP-1 inhibition can potentiate the cytotoxicity of anti-cancer drugs in cancer cells with
functional BRCA1 and suggest that mutations in other DNA repair proteins may render cancer cells more
sensitive to interference with PARP-1 activity.
 2012 Elsevier Inc. 
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Breast cancer is the most common malignancy in women and
the second most prevalent cause of cancer-linked death in women
(for reviews, see [1,2]). It is a conglomerate of diseases of the breast§ Grant sponsor: The work was partially supported by a grant from the Austrian
Funding Agency FWF (grant no. P19894-B11) and by a grant from Center for
International Cooperation & Mobility WTZ (no. PL 06/2012).
Abbreviations: BER, base excision repair; BRCA1, breast cancer type 1 susceptibility
protein; HMC, Hoffman modulation contrast; HR, homologous recombination; NER,
nucleotide excision repair; NHEJ, non-homologous end joining; MMP, mitochon-
drial membrane potential; PARP-1, poly(ADP-ribose)polymerase-1; PD, Petri dish;
PVDF, polyvinylidene diﬂuoride; TOPO, topoisomerase; WCL, whole cell lysate; WT,
wild-type.
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Open access under CC BY-NC-ND license.and arises from the misregulation of several essential cellular
pathways (notably, those controlling cellular metabolism, cell
cycle progression, cell proliferation, and apoptosis), with different
variants having different signature characteristics and family
histories (for reviews, see [3,4]). The identiﬁcation of molecular
signatures for different types of breast cancers over the last two
decades has facilitated the development of targeted therapeutic
strategies (for a review, see [5]).
Individuals with ﬁrst-degree relatives having germline muta-
tions in genes such as breast and ovarian cancer type 1 or 2
susceptibility (BRCA1 or BRCA2) genes are subject to an increased
risk of developing breast cancer [6]. Approximately 5–10% of breast
and ovarian cancers result from inherited alterations or mutations
in these genes. The BRCA1 and BRCA2 proteins are both involved in
repairing double stranded DNA breaks by homologous recombi-
nation (HR), a process that is essential for DNA integrity and the
maintenance of genomic stability [7–9].
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anti-cancer drugs such as alkylating agents, cross-linking agents,
and topoisomerase inhibitors affect the integrity of DNA either
directly or indirectly, resulting in the formation of single or double
stranded breaks (for reviews, see: [10]). If these breaks are not
repaired, the resulting persistent DNA damage can give rise to
mutations and genomic instability that subsequently cause
secondary cancers [11–13] or cell death [14], with the precise
outcome depending on the overall extent of breakage. Interest-
ingly, it has been found that DNA-repair deﬁcient cancer cells (such
as those with BRCA 1/2 mutations) are more sensitive to inhibitors
of poly(ADP-ribose)polymerase 1 (PARP-1), whose primary func-
tions are related to DNA base excision repair (BER) [15–19]. Based
on this observation, a new therapeutic approach termed ‘‘synthetic
lethality’’ has been developed that relies on the conditional
blockage of BER in DNA-repair deﬁcient cancer cells [20].
Treatment with selective inhibitors of PARP-1 (a nuclear enzyme
involved in the signaling of DNA damage and BER) in conjunction
with radiation or cytotoxic anti-cancer agents such as topoisom-
erase (TOPO) type I or II inhibitors can induce severe genomic
instability that leads to cell death. In recent years, the synergistic
beneﬁt of combining PARP-1 inhibition with anti-cancer drug
treatment has been demonstrated in several pre-clinical models,
and multiple PARP-1 inhibitors for use in treatments of this kind
have been developed.
This paper describes an investigation into the sensitivity of
breast cancer cells to C-1305, a selective inhibitor of TOPO II. A
range of cells that differed in terms of the functional status of
BRCA1 and p53 were considered. Different BRCA1-competent
breast cancer cell lines exhibited different responses to C-1305. BT-
20 cells expressing high levels of BRCA1 were most resistant to C-
1305. However, pharmacological inhibition of PARP-1 activity
strongly inhibited their proliferation and potentiated the efﬁcacy
of C-1305 treatment. In contrast, PARP-1 inhibition had only
modest effects on the proliferation of BRCA-1-deﬁcient SKBr-3
cells. These unexpected results indicate that interference with BER
can potentiate the cytotoxicity of anti-cancer drugs in cancer cells
with functional BRCA1 and suggest that mutations in other DNA
repair proteins render cancer cells sensitive to inhibition of PARP-1
activity.
2. Material and methods
2.1. Drugs and chemicals
The triazoloacridone compound C-1305 used in this work was
synthesized at the Department of Pharmaceutical Technology and
Biochemistry (Gdan´sk University of Technology) by Dr. Barbara
Horowska. A stock solution of triazoloacridone (base-free) was
prepared in 0.2% lactic acid. NU1025, an inhibitor of PARP-1 from
AXON Medchem BV (Groningen, Netherlands) and camptothecin
CPT), a quinoline alkaloid which inhibits topoisomerase I, from
Calbiochem-Novabiochem Corporation (La Jolla, CA), were stored
as a stock solution in DMSO. All drugs were stored at 20 8C until
use.
2.2. Cells and treatment
Human primary breast cancer cell lines were purchased from
the American Type Culture Collection (ATCC, Manassas, VA). The
following cell lines were used: human MCF-7, BT-20 [21], and
SKBr-3 [22] breast carcinoma cells. MCF-7 cells were grown as a
monolayer in phenol red-free Dulbecco’s medium supplemented
with 10% fetal calf serum (FCS) at 37 8C under an atmosphere
containing 8% CO2 [23]. SKBr-3 cells were cultivated in DMEM
medium with 10% FCS, and BT-20 cells in RPMI with 10% FCS.Twenty-four hours after plating (at 60–70% conﬂuence), the cells
were treated with the triazoloacridone compound C-1305 at
concentrations ranging from 1 to 10 mM, and with NU1025 at a
ﬁnal concentration of 100 or 200 mM. The two drugs were applied
separately or simultaneously, for the periods of time indicated in
Figs. 2–10.
2.3. Antibodies
The following speciﬁc primary antibodies were used to detect
the relevant proteins: mouse monoclonal anti-p53 antibody DO-1
and rabbit polyclonal anti-H2AX antibody (from BioLegend, San
Diego, CA), anti-BRCA-1 rabbit polyclonal antibody (from Upstate
Cell Signaling Solutions, Lake Placid, NY), anti-ER-a rabbit
polyclonal antibody (from Sigma–Aldrich, St. Louis, MO), anti-
phospho-histone H2AX (Ser139) rabbit polyclonal antibody (from
Cell Signaling Technology Inc., Danvers, MA), anti-DBC-1 mouse
monoclonal antibody (from Abcam plc, Cambridge, UK), and
mouse monoclonal anti-actin antibody (clone C4, ICN Biochem-
icals, Aurora, OH). Appropriate secondary antibodies linked to
horseradish peroxidase (HRP) were obtained from R&D Systems
(Minneapolis, MN).
2.4. Detection of chromatin changes in individual cells by
ﬂuorescence microscopy
Cells grown in 35 mm Petri dishes were treated with C-1305,
NU1025 or a combination of the two for the indicated lengths of
time and then washed three times in PBS. The washed cells were
immediately ﬁxed in 3.7% paraformaldehyde in PBS, then washed 4
times in PBS and stained with Hoechst 33258 dissolved in PBS at a
ﬁnal concentration of 1.5 mg/ml [24]. The stained cells were
inspected under a ﬂuorescence microscope (Eclipse TE300 inverted
microscope, Nikon Corporation, Tokyo).
2.5. Determination of numbers of living cells
The numbers of viable human breast cancer cells and
their sensitivities to the tested drugs at various concentrations
were determined using CellTiter-GloTM assays (Promega
Corporation, Madison, WI). As described previously [25], the
CellTiter-GloTM luminescent cell viability assay measures
luminescent signals, which are correlated with cellular ATP
levels. Tests were performed at least in quadruplicate, and the
cells’ luminescence was measured using a Wallac 1420 Victor
multilabel, multitask plate counter (Wallac Oy, Turku, Finland).
Each data point represents the mean  SD (bars) of replicates
from at least three independent experiments (Figs. 2–4). The
effects of the combined C-1305 and NU1025 treatments are shown
in Fig. 4.
2.6. Quantitative analysis of the mitochondrial membrane potential
by ﬂow cytometry
Mitochondrial depolarization was monitored using the
cationic carbocyanine dye JC-1 (Molecular Probes Inc., Eugene,
OR) as previously described [26]. Control and drug-treated cells
were harvested, washed and incubated with the dye at a ﬁnal
concentration of 10 mM for 5 min followed by extensive
washings in PBS and immediate two-color analysis by ﬂow
cytometry. JC-1 accumulates in the mitochondria of intact cells
if the mitochondrial membrane potential is within the normal
range, forming ﬂuorescent red aggregates known as J-aggregates
that emit at 570 nm in response to excitation at 488 nm.
Mitochondrial depolarization in apoptotic cells causes the
aggregates to dissociate into green ﬂuorescent monomers
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530 nm.
2.7. Determination of the activity of caspase-3/7
The activity of caspase-3/7 was determined using the
Caspase-3-GLO Assay (Promega Corporation, Madison, WI) with
a luminogenic caspase-3/7 substrate harboring the caspase-3/7
DEVD sequence as described previously [24,27]. Human BT-20
breast cancer cells were plated into 96-well microtiter plates.
Twenty-four hours after plating, the cells were treated with C-
1305, NU1025 or a combination of the two as listed in Fig. 9. As a
positive control, BT-20 cells treated for 72 h with CPT at a ﬁnal
concentration of 0.2 and 2 mM were used. After termination of
the treatment, equal volumes of the Caspase-3-GLO reagent were
added and the probes were incubated at 37 8C for different
periods of time to identify the best signal-to-background ratio.
The generated luminescence was measured at intervals of
30 min. The luminescence, which is directly proportional to
the amount of activated caspase-3/7, was measured using a
Wallac 1420 Victor multifunction plate reader (Wallac Oy, Turku,
Finland). The measured caspase-3/7 activity was normalized
against the number of living cells as determined by the CellTiter-
GloTM assay and expressed as a percentage of the control value.
Each data point represents the mean  SD (bars) of two
independent experiments, each of which was performed in
quadruplicate or more.
2.8. Measurement of DNA concentration in single cells by ﬂow
cytometry
The DNA contents of single cells were measured by ﬂow
cytometry using the method of Vindelov [28], with slight
modiﬁcations as described elsewhere [27]. Brieﬂy, the adherent
cells were detached from the substratum by limited trypsiniza-
tion and then all cells were harvested by centrifugation and
washed in PBS. Aliquots of 1  106 cells were stained with
propidium iodide as previously described and their ﬂuorescence
was measured using a Becton Dickinson FACScan ﬂow cytometer
(Becton Dickinson, Franklin Lakes, NJ) after at least 2 h incubation
at +4 8C in the dark. The cellular DNA concentration was evaluated
using ModFIT LTTM cell cycle analysis software (Verity Software
House, Topsham, ME) and DNA histograms were generated using
the CellQuestTM software package (Becton Dickinson, Franklin
Lakes, NJ).
2.9. Single-cell gel electrophoresis (SCGE)
The formation of DNA strand breaks was assessed by the
single cell gel electrophoresis (SCGE) assay performed under
alkaline conditions. The terms ‘‘SSGE’’ or ‘‘Comet’’ are used
interchangeably throughout this report. The experiments were
carried out according to the international SCGE guidelines
[29,30] as described previously [24]. The cells investigated were
human BT-20 breast cancer cells and cells that had been exposed
for 24 h to C-1305 at ﬁnal concentrations of 2 mM and 5 mM, to
NU1025 at a ﬁnal concentration of 100 mM alone, or to some
combinations of the two drugs. Cells were analyzed immediately
after termination of treatment and also after being washed out
and subjected to an additional 48 h’ post-incubation in a drug-
free medium or in media containing 100 mM NU1025. The cells
were harvested in PBS and their viability was determined using
the Trypan blue exclusion test [31]. In all cultures, the cells’
vitality was 80%. Three cultures were prepared in parallel for
each experimental point considered, and for each treatment
150 cells were analyzed for Comet formation. To monitor DNAmigration, cell suspensions (1  105 cells) were mixed with low
melting point agarose (0.5% LMA) and transferred to agarose-
coated slides (1.5% NMA). The slides were then immersed in a
lysis solution (1% Triton X-100, 10% DMSO, 2.5 M NaCl, 100 mM
EDTA, 10 mM Trizma base). After lysis (pH 10.0) and electro-
phoresis (30 min, 300 mA, 1.0 V/1 cm corresponding to 25 V, at
4 8C, pH > 13), the gels were stained with ethidium bromide
(20 mg/ml). The resulting slides were examined under a
ﬂuorescence microscope (Nikon EFD-3, Tokyo, Japan) using
25-fold magniﬁcation. DNA migration was determined based on
tail intensity (% DNA in tail) using a computer-aided Comet assay
image analysis system (Comet Assay IV, Perceptive Instruments,
UK).
2.10. Electrophoretic separation of proteins and immunoblotting
Total cellular proteins dissolved in SDS sample buffer were
separated on 10%, 12% or 15% SDS slab gels, transferred
electrophoretically onto polyvinylidene diﬂuoride membrane
(PVDF) (GE Healthcare UK Ltd, Little Chalfont, Buckinghamshire,
England (formerly Amersham Biosciences) and immunoblotted as
previously described [32,33]. Equal protein loading was conﬁrmed
by Ponceau S staining. To determine the phosphorylation status of
selected proteins, antibodies recognizing site-speciﬁc phosphory-
lated proteins were diluted to a ﬁnal concentration of 1:1000 in 1%
BSA in Tris–saline–Tween-20 (TST) buffer [24]. In some cases, blots
were used for sequential incubations. Immune complexes were
detected after incubation with appropriate HRP-coupled second-
ary antibodies using chemiluminescent ECL PlusTM Western
Blotting Reagents from GE Healthcare. Chemiluminescence was
detected after exposing the blots to ﬁlm or by analysis using
ChemiSmart5100 apparatus (PEQLAB, Biotechnologie GmbH,
Erlangen, Germany).
2.11. Analysis of interactions using the CalcuSyn method
Two methods of interaction analysis were used to determine
whether the drug combination exhibited synergistic, additive, or
antagonistic effects. The ﬁrst was the combination index (CI)
method of Chou and Talalay [34]. The CalcuSyn software package
(Version 2.0, Biosoft, Cambridge, UK), which is based on this
method and takes into account both potency [median dose (Dm) or
IC50] and the shape of the dose-effect curve (the m value), was used
to calculate the combination index (CI). The program automatically
graphs its output and produces reports of summary statistics for all
of the drugs considered, together with a detailed analysis of drug
interactions including the combination index (CI). A combination is
considered to be synergistic if CI <1, additive if CI = 1, and
antagonistic if CI > 1. For this analysis, data were obtained on the
effects of the combined C-1305 and NU1025 treatments at each
tested concentration. The fraction of cells affected and the
corresponding combination index values were calculated for each
concentration.
2.12. Statistical analyses
Statistical analyses were performed using GraphPad Prism
software (GraphPad Software, Inc., La Jolla, CA) and signiﬁcance
levels were evaluated using Bonferroni’s and Dunnett’s Multiple
Comparison Tests. Differences between treatments were deemed
to be extremely signiﬁcant, very signiﬁcant, signiﬁcant and not
signiﬁcant if their p values (according to Bonferroni’s comparison
test) were <0.001, <0.01, 0.01 < p < 0.05 and >0.05, respectively.
In the tables and ﬁgures such differences are indicated by three
asterisks (***), two asterisks (**), one asterisk (*) and no asterisk,
respectively.
Fig. 1. Differential signature of human breast cancer cells examined in this study.
WCLs prepared from four breast cancer cell lines were analyzed by immunoblotting
after separation on 10% SDS slab gels. Blots were incubated with antibodies directed
against BRCA1, DBC-1, ER-a and p53. Immune complexes were detected after
incubation with appropriate secondary antibodies linked to HRP and
chemiluminescence reagent ECL PlusTM (GE Healthcare). Chemiluminescence
was monitored using ChemiSmart5100 apparatus (PEQLAB, Biotechnologie
GmbH, Erlangen, Germany). Equal protein loading was conﬁrmed by Ponceau S
staining of membranes and incubation with anti-actin antibodies. BT-20, SKBr-3
cells and two cell MCF-7 derived cell clones (MCF-7.0 cells transfected with empty
CMV vector and MCF-7.E6 transfected with CMV vector expressing HPV-encoded E6
oncoprotein) were loaded.
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3.1. Differential signature of human breast cancer cells examined in
this study
We initially used immunoblotting to analyze cellular levels of
proteins that are known to be characteristic of the breast cancer
cell lines examined in this work. In keeping with previous reports,
BRCA1 was not detected in SKBr-3 cells [22]. Conversely, BRCA1
was strongly expressed in human BT-20 cells, to an appreciably
greater extent than was observed for MCF-7 cells (Fig. 1). The dual-
acting protein DBC-1 (Deleted in Breast Cancer-1) was expressed at
similar levels in all analyzed cell lines, and p53 protein was
detected in both ER-a negative cancer cell lines (BT-20 and SKBr-3;
to an appreciably greater extent in BT-20 cells). As expected, the
p53 protein was not present at detectable levels in unstressed
control MCF-7 cells that harbor the wt TP53 gene (Fig. 1).Fig. 2. Pharmacological interference with PARP-1 activity strongly inhibits proliferation
cells (BT-20, MCF-7 and SKBr-3) were plated in 96-well microtiter plates and 24 h after 
numbers of viable cells were determined directly after the treatment using CellTiter-GloT
at least three independent experiments, each performed in quadruplicate. Results were
signiﬁcance of the observed reductions in cell numbers following treatment were calculat
(24 h) and very signiﬁcantly (after 48 h) the numbers of viable BT-20 cells. Asterisks locat
the corresponding treatment and the control. Single asterisks denote signiﬁcant diffe
p < 0.001 level.3.2. Pharmacological interference with PARP-1 activity strongly
inhibits proliferation of BT-20 cells with strong expression of BRCA1
Based on previous results, it might have been expected that of
the cell lines tested, those deﬁcient in BRCA1 expression would be
most sensitive to PARP-1 inhibition. Surprisingly however, the cell
line that was most strongly affected by pharmacological interfer-
ence with PARP-1 activity was that with the highest BRCA1 levels –
the BT-20 line (Fig. 2). The anti-proliferative action of the PARP-1
inhibitor was both concentration- and time-dependent, but
continuous treatment for 48 h caused very statistically signiﬁcant
reductions in the number of living BT-20 cells even at the lower
NU1025 dose (CE = 100 mM) (Fig. 2). In contrast, the proliferation of
BRCA1-deﬁcient SKBr-3 cells was almost completely unchanged
after 48 h’ exposure to the PARP-1 inhibitor (Fig. 2).
3.3. BRCA1-deﬁcient SKBr-3 cells are most sensitive to the inhibition
of topoisomerase II by C-1305
In the second phase of the investigation, we determined the
sensitivity of the breast cancer cells to C-1305, a selective inhibitor
of topoisomerase II. Of the tested cancer cells, it was the BRCA1-
deﬁcient SKBR-3 line whose proliferation was most strongly
inhibited by C-1305 (Fig. 3), whereas human BT-20 breast cancer
cells (which have the highest BRCA1 levels of the tested lines) were
most resistant to treatment with C-1305. Treatment with 10 mM C-
1305 for 24 h reduced the number of living BT-20 cells by
approximately 15% whereas the same treatment reduced the
number of living SKBr-3 cells by almost 60%. As previously
reported, C-1305 has a long-lasting effect [24]. After 24 h’ exposure
to C-1305, the treated cells were washed and incubated for 48 h on
drug-free media. Further reductions in the number of living cells
were observed during this post-incubation period (Fig. 3), with the
number of living BT-20 cells falling by approximately 40%. The
number of living cells from the MCF-7 and SKBr-3 lines fell by
almost 85 and 95%, respectively. These results clearly show that
the proliferation of human SKBr-3 cells was most strongly affected
by treatment with C-1305.
3.4. Inhibition of PARP-1 potentiates the efﬁcacy of C-1305 treatment
exclusively in BT-20 cells
Because human SKBr-3 cells were insensitive to PARP-1
inhibition, our subsequent experiments examining the interaction
between PARP-1 inhibition and TOPO-II inhibition focused
exclusively on the human MCF-7 and BT-20 breast cancer lines.
Concurrent inhibition of PARP-1 activity in human MCF-7 cells of BT-20 cells with strong expression BRCA1. Exponentially growing breast cancer
plating were treated with NU1025 at indicated concentrations for 24 h or 48 h. The
M assays (Promega Corporation, Madison, WI). The data represent mean values from
 analyzed using GraphPadPrism software (GraphPad Software, Inc.). The statistical
ed using Dunnett’s Multiple Comparison test. PARP-1 inhibitor reduced signiﬁcantly
ed directly above individual bars denote statistically signiﬁcant differences between
rences at the p < 0.05 level. Triple asterisks denote signiﬁcant differences at the
Fig. 3. BRCA1-deﬁcient SKBr-3 cells are most sensitive to the inhibition of topoisomerase II by C-1305. Exponentially growing human breast cancer cells (BT-20, MCF-7 and
SKBr-3) were plated in 96-well microtiter plates and 24 h after plating were treated with C-1305 at indicated concentrations for 24 h. The numbers of viable cells were
determined directly after the treatment, or alternatively medium was changed and cells were post-incubated in a drug-free medium for 48 h using CellTiter-GloTM assays
(Promega Corporation, Madison, WI). The data were analyzed as described in detail in Fig. 2. Dose–response curves were calculated by nonlinear regression analyses. IC50
values determined from dose–response curves are shown.
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1305 after 24 h (Fig. 4A, left panel). Similarly, pharmacological
inactivation of PARP-1 during the post-incubation of C-1305-
treated MCF-7 cells did not greatly increase the effect of the TOPO II
inhibitor (Fig. 4A, right panel). Notably, changing of the sequence of
drug administration by ﬁrst treating the cells with NU1025 for
24 h, washing, then treating with C-1305 + NU1025 for 48 hFig. 4. Inhibition of PARP-1 potentiates the efﬁcacy of C-1305 treatment exclusively in B
Fig. 2. Cells were treated with C-1305 and NU1025, or their combination at indicated co
signiﬁcance of the observed reductions in cell numbers following treatment was calcul
directly above individual bars denote statistically signiﬁcant differences between the cor
connecting two bars denote statistically signiﬁcant differences between the indicated tre
asterisks denote signiﬁcant differences at the p < 0.01 level. Triple asterisks denote sig(Fig. 4A, right panel) alleviated the anti-proliferative effect of the
TOPO II inhibitor.
In contrast, NU1025 strongly enhanced the cytotoxic effects of
C-1305 on human BT-20 cells (Fig. 4B). Concurrent inhibition of
PARP-1 activity enhanced the cytotoxic effects of C-1305 after
24 h; this effect was statistically signiﬁcant and was more
pronounced at the higher C-1305 concentration (CE = 5 mM)T-20 cells. Human MCF-7 and BT-20 breast cancer cells were plated as described in
ncentrations. The data were analyzed as described in detail in Fig. 2. The statistical
ated using Dunnett’s and Bonferroni’s Multiple Comparison test. Asterisks located
responding treatment and the control. Asterisks located directly at the end of a line
atments. Single asterisks denote signiﬁcant differences at the p < 0.05 level. Double
niﬁcant differences at the p < 0.001 level.
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demonstrate that PARP-1 inhibition with NU1025 can potentiate
the effects of C-1305 even if the former is applied some time later
than the latter. Inactivation of PARP-1 during co-treatment with C-
1305 for 24 h and during the subsequent 48-h post-incubation
doubled the cytotoxic effect of the TOPO II inhibitor (Fig. 4B; right
panel). All of these effects were statistically signiﬁcant. Notably,
increasing the dosage of the PARP-1 inhibitor did not enhance the
cytotoxicity of C-1305.
3.5. The interaction between C-1305 and PARP-1 inhibition in BT-20
cells is strongly synergistic
Our discovery that treating BT-20 cells with a PARP-1 inhibitor
potentiates the anti-proliferative action of C-1305 prompted us to
investigate the interactions between two compounds using the
CalcuSyn software package. The calculated combination index (CI)
was less than 1 for all compound combinations tested, indicating a
synergistic interaction between NU1025 (CE = 100 and 200 mM) and
C-1305 at concentrations ranging from 2 to 5 mM (Table 1). The
interaction was additive (CI  1.011) when BT-20 cells were treated
with 100 mM NU1025 for 24 h and then NU1025 was combined with
5 mM C-1305 during the 48 h post-incubation period. In contrast, the
interaction between the two tested inhibitors in MCF-7 cells was
additive after treatment for 24 h and CI increased to more than 1.2 after
the post-incubation, indicating an antagonistic relationship.
3.6. Interfering with PARP-1 activity has different effects on cell cycle
progression in BT-20 and MCF-7 cells
To determine how NU1025 modulates cell cycle progression in
human BT-20 and MCF-7 breast cancer cells, exponentially
growing cells were exposed to NU1025 for 24 h at ﬁnal
concentrations of 100 and 200 mM. The cells were then harvested
and the DNA concentration of single cells was determined by ﬂow
cytometric measurement of their ﬂuorescence intensity following
propidium iodide staining. In exponentially growing MCF-7 cells,
treatment with the PARP-1 inhibitor for 24 h increased the
abundance of S-phase cells by approximately 10% at the expense
of the G1 cell population (Fig. 5). However, extending the treatment
for a longer period of time (24 h/MC/p.i. 48 h) yielded a
distribution across the phases of the cell cycle similar to that
observed for the untreated controls. In contrast, the number of S-
phase cells decreased slightly when BT-20 cells were treated with
NU1025 for 24 h or for 72 h overall (24 h/MC/p.i. 48 h); this was
accompanied by a modest increase in the proportion of G2-phaseTable 1
Synergistic interaction between C-1305 and NU1025 in BT-20 cells.
24 h 100 mM NU1025 
2 mM C-1305 5 mM
BT-20 0.188 0.12
MCF-7 0.842 0.99
24 h 100 mM NU1025+ 
2 mM C-1305 5 mM
Post-incubation for 48 h 100 mM NU1025 
BT-20 0.449 0.55
MCF-7 1.212 1.01
24 h 100 mM NU1025 
Post-incubation for 48 h 100 mM NU1025+ 
2 mM C-1305 5 m
BT-20 0.544 1.01
MCF-7 1.296 1.28cells. These results indicate that by itself, pharmacological
interference with PARP-1 activity has weak but opposed effects
on cell cycle progression in the two human breast cancer lines
considered in this work.
3.7. Inhibition of TOPO II affects cell cycle progression in human breast
cancer cells
The effect of C-1305 on the distribution of breast cancer cells
across the phases of the cell cycle was dose-dependent. At the
lower dose considered (2 mM), the TOPO II inhibitor caused a
decrease in the abundance of S-phase cells in both lines, with a
corresponding increase in the proportion of G1-phase cells (Fig. 5).
These changes were transient; after washing out and post-
incubation for 48 h in drug-free media, the distribution of cells
across the phases of the cell cycle was similar to that in untreated
control cells. However, at the higher dose (5 mM), C-1305 induced
arrest at the G2/M transition (Fig. 5). C-1305-induced G2 arrest was
more pronounced in MCF-7 cells (in which it caused an
approximately threefold increase in the abundance of G2 cells,
from 15% to 40%) than in BT-20 (18% to 33%), and persisted in both
cell lines after 48 h’ post-incubation in a drug-free medium.
3.8. Impact of concurrent inactivation of PARP-1 and TOPO II on cell
cycle progression
The observed changes in cell cycle distribution became more
pronounced when C-1305 was applied in conjunction with
NU1025 provided that both compounds were applied at the
higher doses (5 mM C-1305 + 200 mM NU1025). In human MCF-7
cells, this combination caused a pronounced reduction in the
proportion of S-phase cells after 24 h, with a corresponding
increase in the abundance of G1-phase cells. In contrast, treatment
of BT-20 cells for 24 h with 5 mM C-1305 in conjunction with
200 mM NU1025 increased the proportion of S-phase cells and
decreased that of G1-phase cells. Taken together, these results
show that inactivation of PARP-1 has very little or no impact on cell
cycle progression and that the combination of the PARP-1 inhibitor
with C-1305 has no signiﬁcant impact on cell cycle progression in
BT-20 cells.
3.9. Chromatin changes after inhibition of TOPO II and PARP-1 in
breast cancer cells
We used in situ monitoring techniques to observe the changes
in cell density and chromatin structure following the inhibition of200 mM NU1025










M C-1305 2 mM C-1305 5 mM C-1305
1 0.623 0.796
4 1.46 1.966
Fig. 5. Interference with TOPO II activity affects differentially the progression of cell cycle in BT-20 and MCF-7 cells. Exponentially growing human BT-20 and MCF-7 breast
cancer cells were treated with C-1305, NU1025 or their combination at indicated concentrations for 24 h. Cells were harvested immediately after treatment or
alternatively medium was changed and cells were post-incubated for 48 h. Harvested cells were stained with propidium iodide. DNA content in single cells was measured
by ﬂow cytometry. (A) DNA histograms obtained from a representative experiment were prepared using Cell Quest software. (B) Comparison of the inhibitors on the
distribution of cells in speciﬁc cell cycle phases. DNA concentrations were evaluated using ModFIT software. The data represent mean values  SD from three independent
experiments.
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Fig. 6. Monitoring of changes in chromatin structure in breast cancer cells after inhibition of TOPO II and PARP-1. (A) Inhibition of PARP-1 strongly reduces the number of BT-
20 cells but not of MCF-7 cells. Images taken at low magniﬁcation (10 objective). (B) Induction of apoptosis and mitotic catastrophe in BT-20 cells after inhibition of PARP-1.
Images taken at higher magniﬁcation (60 objective). Untreated controls and cells treated with C-1305, NU1025 or their combination for 48 h were ﬁxed and stained with
Hoechst 33258. Cell density of monolayer, cell size and phenotype were inspected by light microscopy using Hoffman Modulation Contrast (HMC) and chromatin structure
visualized by Hoechst 33258 staining was monitored by ﬂuorescence microscopy. White bars represent 50 mm. A, apoptosis; AM, aberrant mitosis, M, mitosis; MC, mitotic
catastrophe.
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and cells exposed to either one inhibitor alone or both inhibitors in
tandem were ﬁxed and their chromatin was stained with Hoechst
dye. Unlike MCF-7 cells, BT-20 cells were strongly affected by the
inhibition of PARP-1 (Fig. 6A) and their density decreased
substantially. Both mitotic cells and cells undergoing apoptosis
were detected in the samples. Concurrent inhibition of PARP-1 and
TOPO II caused a much more pronounced reduction in the number
of living BT-20 cells. The proportion of apoptotic cells increased; a
few dividing cells were also observed (Fig. 6B). Moreover, aberrant
mitoses, mitotic catastrophe and apoptotic changes in mitotic cells
were detected. These results indicate that inhibition of PARP-1
triggered apoptosis in BT-20 cells rather than stopping division.
3.10. PARP-1 inhibition causes DNA damage in BT-20 cells
Our next objective was to determine whether inhibiting PARP-1
with NU1025 would have any impact on DNA integrity. It is known
that DNA damage induces site-speciﬁc phosphorylation of the
H2AX protein via activation of stress kinases. We therefore used
immunoblotting to quantitatively monitor changes in the phos-
phorylation status of this protein in breast cancer cells treated with
inhibitors of PARP-1, TOPO II or both (Fig. 7). In MCF-7 cells,
treatment with NU1025 did not cause increased phosphorylation
of H2AX at Ser139 relative to the untreated control sample (Fig. 7).
Surprisingly, PARP-1 inhibition strongly induced phosphorylation
of H2AX in BT-20 cells. Furthermore, at the higher dose
(CE = 5 mM), C-1305 caused a pronounced increase in H2AX
phosphorylation in MCF-7 cells but not in BT-20 cells. However,
inhibition of PARP-1 in BT-20 cells in conjunction with C-1305Fig. 7. PARP-1 inhibitor induces site-speciﬁc phosphorylation of H2AX and changes in p
MCF-7 and BT-20 cells and cells exposed to either one inhibitor alone or both inhib
immunoblotting using indicated antibodies as described in detail in Fig. 1. The intensity o
normalized against actin. Then P-Ser139 H2AX/H2AX ratio was calculated and normalize
was plotted in the diagram.potentiated the phosphorylation of H2AX at Ser139. The changes in
the phosphorylation status of the H2AX protein seem to reﬂect the
sensitivity of both cancer cell lines to the treatment.
3.11. Inactivation of PARP-1 induces caspase-3-dependent apoptosis
in BT-20 cells
Our next objective was to determine whether interfering with
the activity of TOPO II and PARP-1 would promote pro-apoptotic
changes in the studied breast cancer cells. To assess the impact of
pharmacological inactivation of both enzymes on the mitochon-
drial membrane potential (MMP), we monitored the membrane
potential using the electrochromic dye JC-1 [35]. JC-1 is a positively
charged carbocyanine dye whose distribution between the
subcellular compartments depends on the MMP. Untreated control
MCF-7 and BT-20 cancer cells and cells treated with the inhibitors
separately or together were detached from the substratum by
limited trypsinization and then incubated with JC-1. After careful
washing, the cells were immediately analyzed by ﬂow cytometry.
As shown in Fig. 8, the inhibition of TOPO II by C-1305 did not alter
the membrane potential in BT-20 and MCF-7 cells, with ﬂuorescent
red J-aggregates being observed in both cases. After exposure to
NU1025, the JC-1 aggregates disappeared from the mitochondria of
several BT-20 cells and were replaced by the green ﬂuorescent
monomer, which accumulates in the cytosol. Concurrent inhibition
of PARP-1 and TOPO II only caused strong disruption of the MMP
when both inhibitors were used at the higher dose, but the
observed changes were statistically signiﬁcant. Decreases in the
MMP are characteristic of apoptosis; they cause matrix condensa-
tion and redistribution of cytochrome c, thereby facilitating the53 expression in human breast cancer cells. WCLs prepared from untreated control
itors in tandem were separated on SDS slab gels (10 or 15%) and analyzed by
f protein bands representing P-Ser139 H2AX and total H2AX protein in each lane was
d against the ratio calculated for the controls. The relative phosphorylation of H2AX
Fig. 8. Signiﬁcant disruption of the MMP in human BT-20 breast cancer cells after concurrent inhibition of TOPO II and PARP-1. Exponentially growing human MCF-7 and BT-
20 cells were treated with C-1305, NU1025 or their combination at indicated concentrations. After treatment cells were collected and incubated with JC-1 and directly after
washing were analyzed by ﬂow cytometry using the FITC channel for green monomers (Ex/Em = 510/527) and the PI channel for red-J-aggregates (Ex/Em = 585/590). The
population of cells that lost the capability to aggregate JC-1 is shown in diagram. The statistical signiﬁcance of the observed disruption of the MMP after treatment was
calculated using Bonferroni’s Multiple Comparison test. Asterisks located directly at the midpoint of a line connecting two bars denote statistically signiﬁcant differences
between the indicated treatments. Single asterisks denote signiﬁcant differences at the p < 0.05 level. Double asterisks denote signiﬁcant differences at the p < 0.01 level.
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cascade [36]. To determine the induction of downstream steps, the
activity of effector caspases was measured in BT-20. While caspase
3/7 activity was not stimulated by inhibiting TOPO II (Fig. 9), it was
strongly induced by PARP-1 inhibition. Simultaneous inhibition of
PARP-1 and TOPO II also caused high caspase 3/7 activity, and the
increase was statistically signiﬁcant. Collectively, these results
show that inhibition of PARP-1 potentiates a decrease in the MMP
leading to an apoptotic cascade that strongly activates effector
caspases.
3.12. Accumulation of DNA damage in BT-20 cells after inhibition of
PARP-1 and TOPO II
Finally, to assess the DNA damaging activity of C-1305, we
performed a single cell gel electrophoretic (SSGE) analysis. The
level of DNA damage was quantiﬁed by determining the intensity
of the DNA ‘tail’ according to updated international recommenda-
tions [29,30]. Human BT-20 cancer cells were treated with
triazoloacridone and NU1025 alone or in tandem at the indicated
ﬁnal concentrations for 24 h. The cells were analyzed using the
Comet assay immediately after treatment, or alternatively after a
48 h post-incubation in drug-free media or in media containing the
PARP-1 inhibitor. Treatment with C-1305 for 24 h at a ﬁnal
concentration of 2 mM caused a low level of DNA damage in BT-20
cells; the observed increase in tail intensity was not statistically
signiﬁcant (Fig. 10). At a ﬁnal C-1305 concentration of 5 mM, thelevel of DNA damage was somewhat higher. The cytotoxic effects
of PARP-1 inhibition in BT-20 cells were much more pronounced;
the Comets generated following NU1025 treatment had much
greater tail intensities. Co-treatment with both C-1305 and the
PARP-1 inhibitor caused a slight increase in the level of DNA
damage, and the increase in DNA damage on going from TOPO-II
inhibition (C-1305, CE = 2 mM) alone to inhibition of both TOPO-II
and PARP-1 was statistically signiﬁcant. Analyses of DNA damage
in BT-20 cells after 72 h showed that the 48 h post-incubation only
increased tail intensity for cells treated with the topoisomerase II
inhibitor at the lower dose. This puzzling result was explained by
ﬂuorescence microscopy studies, which revealed that following
the initial treatment, the level of DNA damage increased during the
48 h post-incubation period. It should be noted that it is not
possible to determine the intensity of the tail in cells in which
nuclear DNA has been destroyed using the computer-aided Comet
assay image analysis system (Comet Assay IV, Perceptive Instru-
ments, UK); we have addressed this problem previously [37].
4. Discussion
Malfunctions in the control of cell proliferation can be more or
less speciﬁcally countered using drugs that interfere with DNA
replication, cell cycle progression, cell division and transcription.
One possible way of achieving this is by using pharmacological
agents that directly target DNA topoisomerases. Topoisomerases
(of both type I and type II) play a key role in the control of DNA
Fig. 10. Accumulation of DNA strand breaks in BT-20 cells after inhibition of PARP-1. Untre
at indicated concentrations were resolved by electrophoresis and the gels were stained
ﬂuorescence microscope (Nikon EFD-3, Tokyo, Japan) using 25-fold magniﬁcation. DNA 
aided Comet assay image analysis system (Comet Assay IV, Perceptive Instruments, UK). T
Comparison test. Plots = mean  SD of two independent experiments. Asterisks located d
corresponding treatment and the control. Asterisks located directly at the midpoint of a line
treatments. Triple asterisks denote signiﬁcant differences at the p < 0.001 level.
Fig. 9. Inactivation of PARP-1 strongly induces caspase-3 in BT-20 cells. Inhibition of
PARP-1 strongly induces activity of caspase-3 in BT-20 cells. Exponentially growing
BT-20 cells were treated in a multiwell plate with drugs at indicated concentrations.
The activity of caspase-3 was determined in quadruplicate using the Caspase-3 GLO
assay. The activity of the effector caspase [relative luminescence units (RLU)] was
normalized to the numbers of viable cells, determined in parallel by CellTiter Glo
assay. The data represent mean values  SD from two independent experiments. The
statistical signiﬁcance of the activation of caspase-3 after treatment was calculated
using Bonferroni’s Multiple Comparison test. BT-20 cells exposed to CPT for 72 h were
used as a positive control. Asterisks located directly above individual bars denote
statistically signiﬁcant differences between the corresponding treatment and the
control. Asterisks located directly at the end of a line connecting two bars denote
statistically signiﬁcant differences between the indicated treatments. Triple asterisks
denote signiﬁcant differences at the p < 0.001 level.
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transcription and recombination require that the relevant enzymes
have physical access to the chromosomes’ nucleotide bases [40].
Topoisomerases change the topology of nuclear DNA and can
‘‘unwind’’ it, thereby making the nucleotides accessible [41].
Topoisomerase expression is deregulated in many cancer cells
[42]. Inhibiting topoisomerases activity removes the cell’s ability
to change the topology of its DNA and thus blocks DNA synthesis
and sister chromatid segregation. These essential cellular functions
of DNA topoisomerases make them excellent targets for anticancer
drugs [10]. Several pharmacological topoisomerase inhibitors
generate DNA strand breaks. If these breaks remain unrepaired,
they accumulate, leading to apoptosis (for reviews, [10,42]).
There are two types of agents that target topoisomerases, both
of which interfere with at least one step of the enzymes’ catalytic
cycle [10]. Notably, cancer cells carrying mutations in BRCA1/2
exhibit increased sensitivity to topoisomerase inhibitors. The
BRCA1/2 tumor suppressor genes that are often mutated in breast
and ovarian cancers [43] encode proteins involved in DNA repair
processes, mainly in the HR [44–46]. As such, the loss of BRCA1/2 or
disruption of their activity reduces or even eliminates the cells’
ability to properly repair damaged DNA and maintain genome
stability [43,47].
In the study reported herein, we determined the anti-
proliferative and pro-apoptotic effects of C-1305, a selective
inhibitor of topoisomerase II on human breast cancer cell lines
with different BRCA1 and p53 statuses. The lines responded
differently to inhibition of topoisomerase II. BT-20 cells with
strong expression of BRCA1 were resistant to C-1305 whereas
MCF-7 cells and SKBr-3 cells were more sensitive. However,ated human BT-20 cells and cells treated with C-1305, NU1025 or their combination
 with ethidium bromide (20 mg/ml). The resulting slides were examined under a
migration was determined based on tail intensity (% DNA in tail) using a computer-
he statistical signiﬁcance was determined using Dunnett’s and Benferroni’s Multiple
irectly above individual bars denote statistically signiﬁcant differences between the
 connecting two bars denote statistically signiﬁcant differences between the indicated
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were almost equally affected by the inhibition of topoisomerase II.
Our previous studies have shown that the inactivation of PARP-1 in
mouse and human cells greatly enhances the cytotoxic activity of
triazoloacridone C-1305 [24,48]. We attributed this increased
cytotoxicity of NU1025/C-1305 combination to a partial re-
activation of wt p53 pathway in drug-treated HeLa cells and a
more stringent cell cycle checkpoint control during G2/M transi-
tion that was associated with the enhanced cell death by mitotic
catastrophe [48]. These ﬁndings prompted us to determine
whether pharmacological inhibition of PARP-1 might potentiate
the cytotoxicity of C-1305 in breast cancer cells. It has previously
been shown that BRCA1/2 deﬁcient cancer cells are extremely
sensitive to pharmacological inhibition of PARP-1 [15,16]. Based on
these data, one would expect that PARP-1 inhibition in BRCA-1
deﬁcient SKBr-3 cells would be cytotoxic and would enhance the
anti-proliferative effect of the topoisomerase II inhibitor. Surpris-
ingly, this was not the case: pharmacological interference with
PARP-1 had almost no effect on SKBr-3 proliferation and was not
synergistic with the effects of C-1305. In contrast, the PARP-1
inhibitor NU1025 strongly inhibited the proliferation of BT-20
breast cancer cells that express high levels of BRCA1. The decrease
in the number of viable BT-20 cells upon PARP-1 inhibition was
associated with the strong accumulation of cells arrested at the G2/
M transition and concomitant induction of caspase-dependent
apoptosis. Moreover, NU1025 potentiated the efﬁcacy of C-1305
treatment. The interaction between both compounds was highly
synergistic in almost all tested combinations. These unexpected
ﬁndings raised question about the mechanisms of the increased
cytotoxicity of C-1305 when applied in conjunction with the PARP-
1 inhibitor. Further experiments revealed that the inhibition of
PARP-1 in BT-20 cells resulted in the accumulation of DNA strand
breaks and induced caspase-3 dependent apoptosis. These results
seem to indicate that inhibiting PARP-1 can potentiate the
cytotoxicity of anti-cancer drugs in cancer cells with functional
BRCA1 and suggest that mutations in other DNA repair proteins
may render cancer cells more sensitive to interference with PARP-1
activity.
The origin of the synergy between PARP-1 inhibition and C-
1305 was not immediately apparent. A comparison of the site-
speciﬁc phosphorylation of H2AX after inhibition of TOPO II in the
studied breast cancer cells revealed that C-1305 induced
phosphorylation of Ser139 in the H2AX protein in MCF-7 but
not in BT-20 cells. In contrast, NU1025 alone induced phosphor-
ylation of H2AX at Ser139 in BT-20 but not in MCF-7 cells; when
NU1025 was applied in conjunction with C-1305, the abundance of
this H2AX modiﬁcation increased in both cancer cell lines.
However, the increase in H2AX phosphorylation was much more
pronounced in BT-20 cells. The two cell lines differ in terms of
BRCA1 expression and also in terms of the functional status of
TP53. MCF-7 cells express the active wt form of the p53 tumor
suppressor whereas BT-20 cells express an inactive mutant form.
Notably, TOPO II inhibition strongly induced p53 expression in
MCF-7 cells in tandem with the increased H2AX phosphorylation.
Cellular levels of the p53 protein also increased in MCF-7 cells in a
concentration-dependent manner following treatment with
NU1025. This indicates that DNA damage signaling was occurring
in the MCF-7 cells, inducing a cellular response to the inhibition of
the two enzymes whereas in BT-20 cells the response was
primarily due to PARP-1 inhibition alone. PARP-1 is an abundant
nuclear enzyme that exhibits near-ubiquitous expression and has
multiple functions in the cell; it has been reported to be involved in
DNA-damage-dependent remodeling of the chromatin, DNA
repair, replication and recombination, cell cycle control, the
transcription of the wt p53 protein and the regulation of its
stability [49,50]. Studies on PARP-1 knock-out (KO) mice providedimportant evidence for the physiological roles of PARP-1. Overall,
the results obtained using the KO mouse experimental model
revealed that although PARP-1 is dispensable for life, development
and differentiation, life in the absence of PARP-1 is associated with
increased genomic instability because it reduces the cell’s ability to
detect and repair DNA lesions. The strong sensitivity of BT-20 cells
to PARP-1 inhibition and the associated accumulation of DNA
strand breaks seems to be indicative of a DNA repair deﬁciency in
this line.
Damage to cellular genetic material is an ongoing threat to both
a cell’s ability to maintain genetic stability and to the error-free
transmission of genetic information to daughter cells. DNA can be
damaged spontaneously during DNA metabolism or normal
cellular metabolism. Breaks in DNA strands can be generated by
the free radicals (e.g. oxygen radicals and other reactive oxygen
species) that are formed as products of cellular respiration [51].
Moreover, environmental damage to DNA can be caused by
exogenous chemical or physical factors [52]. In the context of the
results collected in this study, it should be noted that numerous
drugs (including topoisomerase inhibitors) cause severe damage to
DNA in both cancerous and healthy cells. Serendipitously, while
DNA can be damaged in various ways, it is also amenable to repair.
Indeed, cells have various means of repairing DNA, which are
important if the accumulation of DNA damage and the resulting
genomic instability are to be avoided. The cellular response to DNA
damage signaling is dependent on the type of lesions present and
involves the activation of factors involved in the appropriate repair
pathways. Base-excision repair (BER), nucleotide-excision repair
(NER) and mismatch-repair (MM) are essential for the elimination
of single-strand breaks (SSB), whereas HR [53,54] and NHEJ [55,56]
serve to repair double strand breaks (DSBs). The DNA damage
signaling and repair pathways are regulated by a number of
cellular proteins. The functional status of these proteins and the
smoothness of their coordination determine the efﬁcacy of DNA
repair. PARP-1, a nuclear enzyme, is a very sensitive detector of
DNA breaks [57,58]. Remarkably, there are several points of
overlap and redundancies in the various signaling and repair
pathways.
These overlaps are illustrated by the case of breast and ovarian
cancer type 1 susceptibility protein (BRCA1), which is a tumor
suppressor [8]. BRCA1 is a large protein that contains an amino-
terminal RING domain and is a crucial component of the HR-
mediated repair of DSBs [59,60]. However, it can also participate in
other DNA repair pathways such as NER [45], NHEJ [44] and
transcription-coupled repair [61]. BRCA1 is expressed during the S-
and G2-phases of the cell cycle and forms stable complexes with
BRCA1-associated RING domain protein 1 (BARD1) via its RING
domain [62]. BRCA1, a phosphoprotein, harbors at least 14 serine
residues that can be modiﬁed by several protein kinases (reviewed
in [63]). At least seven potential residues ﬁtting ATM’s modiﬁca-
tion motif (S/T-Q) are phosphorylated by ATM kinase in vitro and in
vivo. DNA damage triggers ATM/ATR-dependent phosphorylation
of histone H2AX at Ser139 (H2AX phosphorylated in this way is
known as g-H2AX) [64]. Subsequently, g-H2AX recruits mediator
of DNA damage checkpoint 1 (MDC1), which in turn mediates the
accumulation of the E3 ligase RNF8 complex to promote
ubiquitylation of histones and other proteins at the sites of DNA
breaks and optionally RNF168 [65]. In response to DNA injury,
BRCA1 is rapidly phosphorylated, prompting its relocation to
damage-induced foci whose position is marked by the g-H2AX)
[64]. At these foci, BRCA1 is recruited by RAP80 and co-localizes
with the DNA repair protein RAD51 [66], the meiotic recombina-
tion 11 (MRE11)-RAD50-NBS1 (nibrin) protein (MRN complex) and
several other proteins involved in DNA damage signaling and
repair such as ABRAXAS, BRCA2, CtBP-interacting protein (CtIP),
Receptor-Associated Protein 80 (RAP80), Mediator of Rap80
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Localizer of BRCA2 (PALB2 also known as FANCN). This process
generates multiple macro-complexes (for a review, see [8]). This
raises a question: how does BRCA1 regulate DNA repair? It seems
to play at least two roles at damage-induced foci. First, it acts as a
scaffolding factor that facilitates ATM/ATR-mediated signaling
(which in turn affects the activity of proteins such as p53, nibrin,
Chk1 and Chk2). Second, it recruits speciﬁc proteins involved in
the regulation of DNA repair and coordinates their assembly [8].
To facilitate HR-mediated repair, DSBs need to be processed to
generate ssDNA sections. These then allow the recruitment of the
RAD51 protein. There is evidence suggesting that BRCA1 might
also participate in DNA end resection, thereby facilitating the
formation of RAD51 nucleoprotein ﬁlaments [8]. The ﬁnding
discussed above indicate that the BRCA1 protein has important
function in the maintenance of genome integrity via processes of
DNA replication and repair, especially in the error-free repair of
DSBs by HR [8]. In the absence of BRCA1, HR is impaired and DSBs
have to be processed using alternative mechanisms such as the
error-prone NHEJ. However, considering the complexity of the
DNA repair pathways, it is conceivable that deﬁcits in other
proteins involved in HR or components of the DNA damage
signaling machinery could also severely hinder the repair of
damaged DNA.
Deﬁcit(s) in DNA repair provided a rationale for the
development of synthetic lethality, a new therapeutic strategy.
According to the concept of synthetic lethality, dysfunctions in
either of the DNA repair genes alone would be compatible with
cell viability but simultaneous mutation (inactivation) of both
would cause cell death. Our results clearly indicate that
pharmacological inhibition of PARP-1 is conditionally synthetic
lethal in BT-20 but not in MCF-7 or SKBr-3 breast cancer cells.
These observations are consistent with recent reports indicating
that synthetic lethality can be achieved in cancer cells carrying
mutations in other DNA repair genes. Thus, cells carrying bi-
allelic mutations in the phosphatase tensin homolog (PTEN)
display defects in HR and are sensitive to PARP-1 inhibition
[67,68] Furthermore, ATM-deﬁcient mantle cell lymphoma cells
(MTL) that are defective in DNA damage signaling and cell cycle
checkpoint control are more sensitive to PARP-1 inhibitors than
the ATM-proﬁcient MCF cells [69].
The selectivity of PARP inhibitors toward cancer cells, together
with their suitability for use in tandem with other drugs and in
multimodal therapies make them promising agents for use clinical
oncology.
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